Jazz Pharmaceuticals is transitioning from Xyrem to Xywav, a low-sodium version with lower cardiac risks but faces competition with more convenient dosing. Strong management with CEO Bruce Cozadd ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback